Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) and HCW Biologics (NASDAQ:HCWB – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk.
Institutional and Insider Ownership
3.0% of HCW Biologics shares are owned by institutional investors. 5.4% of Agios Pharmaceuticals shares are owned by company insiders. Comparatively, 9.1% of HCW Biologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Agios Pharmaceuticals and HCW Biologics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Agios Pharmaceuticals | -418.24% | -35.67% | -33.06% |
| HCW Biologics | -83.03% | -262.33% | -34.90% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Agios Pharmaceuticals | 1 | 4 | 5 | 1 | 2.55 |
| HCW Biologics | 1 | 0 | 1 | 0 | 2.00 |
Agios Pharmaceuticals presently has a consensus target price of $41.25, indicating a potential upside of 22.77%. HCW Biologics has a consensus target price of $30.00, indicating a potential upside of 1,239.29%. Given HCW Biologics’ higher probable upside, analysts plainly believe HCW Biologics is more favorable than Agios Pharmaceuticals.
Volatility & Risk
Agios Pharmaceuticals has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, HCW Biologics has a beta of 2.37, suggesting that its stock price is 137% more volatile than the S&P 500.
Valuation and Earnings
This table compares Agios Pharmaceuticals and HCW Biologics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Agios Pharmaceuticals | $54.03 million | 37.13 | -$412.78 million | ($7.01) | -4.79 |
| HCW Biologics | $50,000.00 | 82.43 | -$7.96 million | ($27.60) | -0.08 |
HCW Biologics has lower revenue, but higher earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.
Summary
HCW Biologics beats Agios Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
About HCW Biologics
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
